Objectives: This study aimed to determine anti-coagulant treatment patterns and stroke-and bleeding-related risk factors and to evaluate quality of life (QoL) in nonvalvular atrial fibrillation (NVAF) patients. MethOds: This multicenter (12-centers), observational study included ≥ 18 year-old patients (n= 213) diagnosed with NVAF. CHADS 2 , CHA 2 DS 2 -VASc, HAS-BLED scores and EQ-5D scale were used to assess risk factors and QoL and clinical features were recorded at baseline, and 6 th and 12 th months. Results: The rate of adverse events was 64.7%, major bleeding was 10.8%, stroke was 5.9%, and hospitalization was 25.5% in one-year follow-up. The patients' treatment patterns were grouped as warfarin, new oral anti-coagulant (NOAC) (dabigatran, rivaroxaban), and antiplatelet agents (AA) (acetylsalicylic acid, clopidogrel). Patient numbers for the groups at baseline, and 6 th and 12 th months, respectively, were 92, 74, 41 for warfarin, 2, 13, 14 for NOAC, and 39, 29, 26 for AA. The distribution of patients in the warfarin, NOAC, and AA groups regarding CHADS 2 ≥ 2 was 53.8% (n= 49), 50% (n= 1), and 63.2% (n= 24), respectively; regarding CHA 2 DS 2 -VASc≥ 2 was 86.8% (n= 79), 50% (n= 1), and 89.5% (n= 34), respectively; and regarding HAS-BLED≥ 3 (high bleeding risk) was 23.1% (n= 21), 0% (n= 0), and 18.4% (n= 7), respectively. EQ-5D scale scores were 0.85±0.12 and 0.76±0.13 at baseline and 0.67±0.29 and 0.62±0.37 at 12 th month for the warfarin and AA groups, respectively; the decrease was significant in the warfarin group (p= 0.002) but not in the AA group (p= 0.249). The mortality rates of the patients in the warfarin, NOAC, and AA groups in one-year follow-up were 7.6%, 0.0%, and 10.3%, respectively. cOnclusiOns: Our study has demonstrated that a significant number of patients who should be on oral anticoagulants are still treated with AA and the negative effects of warfarin on QoL of NVAF patients as compared to AA. More data is needed with head-to-head comparison of warfarin and NOAC.

No abstract

No abstract

A651of life (QoL) and the ability to work (WA) too. Till now in the Slovak Republic there was not realised the study oriented on the both mentioned categories. Methods: 102 patients with LC were studied. The average of age was 50.3 y., weight -78.3 kg, height -175.1, duration of illness -2.4 y., symptoms of illness before diagnosis -1.2 y. Metastases were present in 72 patients. 4 patients were mentioned as strong pessimists, 10 predominant pessimists, 9 neither pessimists nor optimists, 61 predominant optimists, and 18 strong optimists. QoL and the ability to work was evaluated by means of the numeric scale from 0 to 10 (0-the worst, 10-the best) by patients themselves. Results: The QoL was evaluated in these domains: in the time of good health -8-21, in the time of diagnosis -2.82, in the current time -3.71. The WA had these results: in time of good health -8.89, in the time of diagnosis -5.08, and in the current time -2.17. The impact of treatment on the QoL was 2.49 and on the patients families QoL it was 2.75. The willingness to pay for perfect cure was 92.35 € per month (the average salary in Slovakia in 2013 was 824 € ). ConClusions: LC has a great impact on QoL and on the WA too. There was a strong correlation between QoL and WA, although the WA has the later onset as QoL. Our research confirmed the importance of early diagnosis and high effective treatment of this disease.

Objectives: The prevalence of urinary incontinence (UI) in women in Slovakia is about 240 000 cases and has an increasing trend. Only 5 % of them were diagnosed by visiting urology or gynecology outpatient department. The objective of this paper was to find out the level of QoL in women with UI in Slovakia. MethOds: The primary method used for the analysis of QoL was the combined questionnaire consisting of 6 parts: A. Demography (9 items), B. Clinical part (B1-International Consultation on Incontinence (ICIQ-SF): 4 items, B2-characteristics of UI: 23 items), C. Quality of life with dominant numeric scale (13 items), D. Socio-economic part (9 items), E. EQ-5D (5 items), F. Symptoms of disease (9 items). There were 112 patients in the examined group from the160 asked to fill the questionnaire. The average age was 61 years. Results: Present level of QoL was identified as 6,60 on the scale from 1 to 10 (1-the worst,10 -the best), while in the time of the UI diagnosis it was 5,10. QoL was 8,10 in the time without UI and 9,40 in the total optimal state of health. Comparative to the QoL was examined the ability to work (AW), too. Present level of AW was identified as 6,50, while in the time of the BC diagnosis it was 5,50. AW was 8.20 in the time without UI and 9,40 in the total optimal state of health. The impact of treatment on QoL was 7,60 and the disease had impact 7,40 on family QoL. The average income was 465,04 € and the willingness to pay for 1 month of complete health was in average 391,06 € . cOnclusiOns: The disease had a significant impact on patients´s QoL. The treatment of UI had a significant impact on increasing QoL of patients.